Indication intelligence, analysis and sector perception

RegMed Investors’ (RMi) closing bell: volatility is still the stimuli of the sector

November 1, 2018 7:11pm

Sentiment is bubbling enhanced by trading of the oversold, fundamentals are improving and risks are being mitigated so far by quarterly results in some cases

Pre-open indications: 1 HIT and 2 MISS

I’ll take a slap on the wrist for my forecast miss on NTLA on earnings and a trial delay but, they are seeing a high that will dissipate – the trust factor of communication still smacks of deception!

Quarterly results: bluebird bio (BLUE) reported a loss of -$145.5 M or -$2.73 per share as compared to Q3/17’s $78.8 M or -$1.73. Revenue was $11.5 M. Cash as of 9/30/18 were $2 B compared to $100.9 M as of 12/31/17. Fate Therapeutics (FATE) reported a net loss of $16.76 M or -$0.31 per share as compared to Q3/17’s $10.6 M or -$0.26. Revenue was $1 M. Cash as of 9/30/18 were $211.2 M compared to $100.9 M as of 12/31/17. Interesting balance sheet number, accounts payable and accrued expenses = 14.97 M.

Who is defining the metrics for individual investors?

The next few trading sessions will be critical for the RegMed sector which will establish whether market reaction this month is temporary and short-lived, or if this is the start of a more fundamental correction.

Members only. Please login.

35 companies, 1 interpreter!

Insight, foresight and recommendation

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.